A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)

Abstract

Background:Elderly cancer patients form a heterogeneous population in which therapeutic decision-making is often difficult. The aim of this randomised phase II trial was to evaluate the feasibility and activity of weekly docetaxel/gemcitabine (DG) followed by erlotinib after progression (arm A) vs erlotinib followed by DG after progression (arm B) in fit… (More)
DOI: 10.1038/bjc.2011.331

Topics

9 Figures and Tables

Cite this paper

@inproceedings{Lecaer2011AMP, title={A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)}, author={H. Lecaer and Fabrice Barl{\'e}si and Romain Corre and H. Jullian and Suzanna Bota and Lionel Falchero and Alain Vergnen{\'e}gre and C{\'e}cile Dujon and J. Y. Delhoume and Christos Chouaid}, booktitle={British Journal of Cancer}, year={2011} }